RxDoctor Payments Data

Horace Cline, MD

Family Medicine · Rome, GANPI 1154345353

Payments from drug & device makers

$868in general payments, 2019–2025

Across 60 payments — averaging $14.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$350
  • Johnson & Johnson$150
  • Exact Sciences$122
  • Novo Nordisk$80
  • Otsuka America Pharmaceutical, Inc.$50
  • Pfizer$45
  • plus $71 from 3 others

What the payments were for

  • Food & beverage$868100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$868 in reported general payments places this provider in the 55th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$84,631
Medicare patients
173
Services billed
1,022

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban362$60,162
LinzessLinaclotide28$16,494
JardianceEmpagliflozin99$15,197
JanuviaSitagliptin Phosphate59$13,199
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,895
TrulicityDulaglutide12$11,526
ZenpepLipase/Protease/Amylase41$9,243
XareltoRivaroxaban50$7,596
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$7,574
ArexvyRsvpref3 Antigen/As01e/Pf24$7,270
FarxigaDapagliflozin Propanediol45$6,602
Spiriva RespimatTiotropium Bromide11$6,025
MyrbetriqMirabegron35$4,042
Divalproex Sodium382$3,928
Sucralfate167$3,359

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$45$60,162362 claims
AbbVieLinzess$350$16,49428 claims
Lilly USA, LLCTrulicity$42$11,52612 claims
Johnson & JohnsonXarelto$150$7,59650 claims
AstraZenecaFarxiga$14$6,60245 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Rome

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →